Companies › Jiangsu Alphamab Biopharmaceuticals
5 active drug programs in 9 registered trials: 7 Phase 1, 2 Phase 3; Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| JSKN003 HER2-targeting antibody | – | Phase 3 | Breast Cancer; Advanced Solid Tumor | Dec 2026 |
| JSKN016 | – | Phase 3 | Triple Negative Breast Cancer; Advanced Malignant Solid Tumor; Inoperable Locally Advanced HER2-Negative Breast Cancer; Advanced Non-small Cell Lung Cancer | Dec 2026 |
| JSKN022 | – | Phase 1 | Advanced Malignant Solid Tumors | Aug 2027 |
| Furmonertinib Mesylate EGFR tyrosine kinase inhibitor | EGFR | Phase 1 | Advanced Non-small Cell Lung Cancer | Jun 2028 |
| JSKN021 | – | Phase 1 | Advanced Malignant Solid Tumors | Oct 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05744427 | JSKN003 | Phase 1 | Advanced Solid Tumor | Oncology | Dec 2026 |
| NCT06592417 | JSKN016 | Phase 1 | Advanced Malignant Solid Tumor | Oncology | Dec 2026 |
| NCT06942234 | JSKN016 | Phase 1 | Inoperable Locally Advanced HER2-Negative Breast Cancer | Oncology | Jun 2027 |
| NCT07292402 | JSKN022 | Phase 1 | Advanced Malignant Solid Tumors | Oncology | Aug 2027 |
| NCT06868732 | JSKN016 | Phase 1 | Advanced Non-small Cell Lung Cancer | Oncology | Jun 2028 |
| NCT06868732 | Furmonertinib Mesylate | Phase 1 | Advanced Non-small Cell Lung Cancer | Oncology | Jun 2028 |
| NCT07617727 | JSKN021 | Phase 1 | Advanced Malignant Solid Tumors | Oncology | Oct 2028 |
| NCT06079983 | JSKN003 | Phase 3 | Breast Cancer | Oncology | Mar 2029 |
| NCT07533123 | JSKN016 | Phase 3 | Triple Negative Breast Cancer | Oncology | Mar 2029 |
AstraZeneca Shanghai Henlius Biotech Allist Pharmaceuticals Dizal Pharmaceuticals Betta Pharmaceuticals Jiangsu Hansoh Pharmaceutical Johnson & Johnson (Janssen) Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Shanghai JMT-Bio Chia Tai Tianqing Pharmaceutical Group
Nanjing Sanhome Pharmaceutical ArriVent BioPharma Jiangsu Aosaikang Pharmaceutical HC Biopharma Wayshine Biopharm
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.